CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · IEX Real-Time Price · USD
57.90
+1.09 (1.92%)
At close: Jul 12, 2024, 4:00 PM
58.60
+0.70 (1.21%)
Pre-market: Jul 15, 2024, 7:46 AM EDT

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.

The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.

It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.

It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.

CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG
CRISPR Therapeutics AG logo
Country Switzerland
IPO Date Oct 19, 2016
Industry Biotechnology
Sector Healthcare
Employees 407
CEO Dr. Samarth Kulkarni Ph.D.

Contact Details

Address:
Baarerstrasse 14
Zug, V8 CH-6300
Switzerland
Phone 6173154600
Website crisprtx.com

Stock Details

Ticker Symbol CRSP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001674416
CUSIP Number H17182108
ISIN Number CH0334081137
Employer ID 47-3173478
SIC Code 2836

Key Executives

Name Position
Dr. Samarth Kulkarni Ph.D. Chief Executive Officer and Chairman
James R. Kasinger General Counsel and Secretary
Shaun Foy Founder
Dr. Emmanuelle Marie Charpentier Co-Founder and Scientific Advisory Board Member
Dr. Craig C. Mello Ph.D. Scientific Founder and Advisory Board Member
Dr. Chad A. Cowan Ph.D. Scientific Founder
Dr. Matthew Porteus M.D., Ph.D. Scientific Founder and Advisory Board Member
Dr. Daniel G. Anderson Ph.D. Scientific Founder and Advisory Board Member
Dr. Raju Yashaswi Prasad Ph.D. Chief Financial Officer
Stephen Kennedy Head of Technical Operations

Latest SEC Filings

Date Type Title
Jun 3, 2024 8-K Current Report
May 23, 2024 8-K Current Report
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
Apr 15, 2024 144 Filing
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 9, 2024 ARS Filing
Apr 9, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 9, 2024 DEF 14A Other definitive proxy statements
Mar 27, 2024 PRE 14A Other preliminary proxy statements